Last reviewed · How we verify
Nydran (BECLAMIDE)
Nydran (generic name: BECLAMIDE) is a beclamide drug. It is currently in Phase 2 development.
Beclamide is thought to work by inhibiting a specific enzyme or protein, but the exact details of its mechanism are not well understood.
Nydran (Beclamide) is a small molecule drug in the beclamide class, but its target and exact mechanism of action are unknown. It is not clear if it is FDA-approved or commercially available. Beclamide is a type of medication that may be used to treat certain conditions, but its specific indications are not well-documented. The commercial status of Nydran is also unclear, and it may be patented or available as a generic medication. Further research is needed to understand the safety and efficacy of Nydran.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | BECLAMIDE |
|---|---|
| Drug class | beclamide |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Imagine your body's cells are like a factory, and enzymes are the workers that help things get done. Beclamide is like a tool that tries to stop one of those workers from doing its job, but we're not entirely sure which worker it is or how it does it. This can help slow down or stop certain processes in the body that might be contributing to a disease or condition.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nydran CI brief — competitive landscape report
- Nydran updates RSS · CI watch RSS
Frequently asked questions about Nydran
What is Nydran?
How does Nydran work?
What is the generic name of Nydran?
What drug class is Nydran in?
What development phase is Nydran in?
Related
- Drug class: All beclamide drugs
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing